New York, NY -- (SBWIRE) -- 06/25/2013 -- Corporate Profile, LLC announced today that Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), CEO Dr. Peter Suzdak was interviewed on www.CorporateProfile.com.

To view directly: http://www.corporateprofile.com/2013/06/24/corporate-profile-interviews-dr-peter-suzdak-ceo-of-rexahn-pharmaceuticals-rnn/

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and RX-5902 and a robust pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of nano-medicines, 3D-GOLD, and TIMES. For more information, please visit http://www.rexahn.com.

About Corporate Profile®
Corporate Profile® is a multi-media news provider, creating original daily news segments and interviews covering topics including finance, fashion, medicine, charitable causes, lifestyle, and wellness through http://www.corporateprofile.com. Financial segments are broadcast on http://www.cpreports.com, which provides viewers and readers fresh, original, and highly informative ideas and market commentary from Wall Street.

Safe Harbor Disclaimer
Under The Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectation.